Clinical trials: Advanced Esophageal Cancer
Gastric Cancer, Colon Cancer
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT05538195
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Esophageal Cancer
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
We intend to conduct a prospective single-arm clinical study to explore the efficacy and safety of immunochemotherapy in neoadjuvant therapy in elderly patients with advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06403878
- Testing
- Carboplatin, Nab paclitaxel, Sintilimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sichuan University
Non-small Cell Lung Cancer, Small Cell Lung Cancer
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
The purpose of this study is to compare two types of care - standard oncology care and standard oncology care with early palliative care (started soon after diagnosis) to see which is better for improving the experience of…
- Conditions
- Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer
- Trial name
- NCT01401907
- Testing
- early palliative care
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Massachusetts General Hospital
First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Conditions
- First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel, Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Trial name
- XP versus XT (NCT00816634)
- Testing
- Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Trial name
- NCT02262455
- Testing
- STM 434, Liposomal doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Santa Maria Biotherapeutics
Esophageal Adenocarcinoma
Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer
Esophageal adenocarcinoma (EAC) is one of the few cancers with a rising incidence in the United States, with an estimated 17,000 new cases diagnosed in 2012.
- Trial name
- NCT02606396
- Testing
- Cryotherapy, Esophagogastroduodenoscopy (EGD), Endoscopic ultrasound (EUS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer
Futibatinib in Patients With Specific FGFR Aberrations
The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts.
- Conditions
- Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
- Trial name
- NCT04189445
- Testing
- Futibatinib
- Where
- 61 sites in United States, Belgium and 13 more
- Volunteers
- 115 people
- Sponsor
- Taiho Oncology, Inc.
Stage III Esophageal Squamous Cell Carcinoma
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
The purpose of this study is to determined the best scheme in paclitaxel and cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy for patients with local advanced esophageal Squamous Cell…
- Trial name
- NCT02459457
- Testing
- Paclitaxel and Cisplatin, Paclitaxel and Fluorouracil, Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Fudan University
HER2-Expressing Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors.
- Trial name
- NCT07334119
- Testing
- MT-304, MT-304 + Nivolumab
- Where
- 7 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Myeloid Therapeutics
ESCC, TAS 102
TAS-102 Plus Radiotherapy in Elderly ESCC
This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.
- Conditions
- ESCC, TAS 102, Radiotherapy
- Trial name
- NCT07196345
- Testing
- TAS-102, Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Qianfoshan Hospital
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Esophageal Cancer, ESCC
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic…
- Trial name
- NCT07770672
- Testing
- Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus Chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tan Lijie
Esophageal Squamous Cell Carcinoma (ESCC)
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
Esophageal cancer is a high - incidence cancer type in China, characterized by high incidence, high mortality, and low survival rates.
- Trial name
- NCT06863831
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a prospective, single-arm, open-label，multi-center, phase Ib/II study, aiming to evaluate the efficacy and safety of Fruquintinib combined With Cadonilimab (AK104) and Tegafur，Gimeracil and Oteracil Potassium in patients…
- Trial name
- NCT06487702
- Testing
- fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Rui-hua Xu, MD, PhD
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation
- Trial name
- NCT06560645
- Testing
- PRT7732
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 42 people
- Sponsor
- Prelude Therapeutics Incorporated
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
- Trial name
- NCT05469061
- Testing
- Tislelizumab, 5-FU, cis Platinum
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
The aim of this study is to investigate the effect of postoperative concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03600831
- Testing
- Docetaxel plus cisplatin, radiotherapy
- Where
- 4 sites in China
- Volunteers
- 434 people
- Sponsor
- Huai'an First People's Hospital
Esophageal Squamous Cell Carcinoma
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression…
- Trial name
- NCT06644781
- Testing
- Ifinatamab deruxtecan, Docetaxel, Paclitaxel
- Where
- 168 sites in United States, Belgium and 15 more
- Volunteers
- 510 people
- Sponsor
- Daiichi Sankyo